Researchers tested VER-01, an experimental cannabis extract, on patients with persistent lower back pain. Patients reported meaningful pain reductions after months of treatment. Unlike smoking cannabis, the extract delivers controlled doses without harmful combustion effects. Scientists designed VER-01 to target pain while minimizing risks of addiction or severe complications. Chronic back pain affects more than 619 million people globally, making it the most common cause of disability. Conventional painkillers like opioids carry high addiction potential, while NSAIDs raise cardiovascular and gastrointestinal risks. For many, treatment options remain limited and ineffective, highlighting the urgent need for safer alternatives.
Clinical Trial Provides Strong Evidence
The clinical trial enrolled 820 adults who struggled with chronic back pain despite non-opioid medication. Half received VER-01, developed by German firm Vertanical, while the rest received a placebo. Participants tracked their pain on a 0–10 scale, with 10 being worst. After three months, the VER-01 group recorded an average 1.9-point reduction in pain, while the placebo group saw only 0.6 points. Researchers extended the trial six more months, during which VER-01 patients experienced another 1.1-point decline. Patients also reported better sleep and improved mobility. These findings, published in Nature Medicine, demonstrate significant clinical benefits. Jan Vollert of the University of Exeter praised the trial, stressing its relevance for millions of sufferers. He warned, however, that additional studies are essential to confirm the results.
Safety, Side Effects, and Future Outlook
Patients taking VER-01 mainly experienced mild dizziness, nausea, and temporary drowsiness. Importantly, researchers observed no evidence of abuse, dependency, or long-term safety issues. VER-01 contains 2.5 milligrams of THC per dose, alongside other compounds from Cannabis sativa. The extract delivers therapeutic benefits while avoiding the psychoactive effects commonly linked with recreational marijuana. Experts emphasize that smoking cannabis differs completely from taking VER-01. Vollert compared the two to eating hazelnuts versus eating Nutella: similar origins but entirely different outcomes. The study team plans additional trials comparing VER-01 directly with opioid treatments. Researchers hope to establish VER-01 as a reliable alternative that reduces pain while lowering risks of addiction. If larger trials confirm its efficacy, the extract could transform treatment for chronic back pain worldwide.
